In conclusion, the current study provided evidence that CPT treatment could potentially enhance the anti-tumour immune response in HCC patients through increasing the plasma levels of CD4, CD8, IL-2, IL-12, and IFN-γ after CPT administration. The gene discussed is CD8A; the disease is hepatocellular carcinoma.